Astellas’ Drug Discovery Strategy: Focus on Oncology

Yutaka Yanagita1,* and Toichi Takenaka2

1Research Strategy, Research Planning and Administration, Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi and 2Astellas Pharma Inc., Tokyo, Japan

*For reprints and all correspondence: Yutaka Yanagita, Astellas Pharma Inc., Tsukuba Research Center, 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. E-mail: yutaka.yanagita@astellas.com

Received December 8, 2011; accepted January 25, 2012

Based on the goal of delivering innovative and reliable pharmaceutical products to cancer patients for whom no effective treatments exist, Astellas is focusing its efforts on a strategy of precision medicine in its drug discovery which is carried out at three research sites with diversity in their research platforms and research styles.

Key words: Astellas – oncology – drug – discovery – strategy

INTRODUCTION

Astellas Pharma Inc. was formed in April 2005 by the merger of two research and development (R&D)-driven companies, namely Yamanouchi Pharmaceutical Co., Ltd, and Fujisawa Pharmaceutical Co., Ltd. ‘Astellas’ expresses the idea of ‘aspired stars’ and ‘advanced stars’ based on the Latin ‘stella’, Greek ‘aster’ and English ‘stellar’, which all refer to ‘stars’. ‘Astellas’ also sounds like the Japanese phrase ‘a-su wo te-ra-su’ which means ‘to shine on tomorrow’ (1).

In this paper, we describe our drug discovery strategy in view of our guiding principles, current research activities and future perspectives, with a particular focus on oncology.

OUR GUIDING PRINCIPLES: PHILOSOPHY, MESSAGE AND VISION

At our very start, we clarified our guiding principles as our philosophy, corporate message and vision. Our philosophy is to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Our corporate message is that we will be the ‘Leading Light for Life’ to deliver world-class state-of-the-art pharmaceuticals that promise people from around the world a healthier life (2). For patients and their families and for ourselves, we have further condensed our message into the phrase ‘Changing tomorrow’ (3).

We went on to decide ‘VISION 2015’ as our management vision in order to show how Astellas must look in the year 2015. In this vision, we constructed our business model, a ‘Global Category Leader’ (GCL). A GCL shows high competitiveness by providing value-added products globally in several categories where high unmet medical needs exist and a high degree of expertise is required, and thereby takes a leading position in such ‘categories’. At the same time, we established our important R&D categories including urology, immunology including transplantation and infectious diseases, neuroscience, diabetes mellitus complications and metabolic diseases, and oncology (4).

OUR RESEARCH PLATFORM

We strongly believe that we need to reinforce our research capabilities by approaching new technologies and new research areas in a timely manner in order to create innovative drugs (5). In 2009, we started operation of an X-ray beam line at the Photon Factory of the High Energy Accelerator Research Organization, Tsukuba, purposely built for efficient elucidation of protein structures for use by Astellas and academic institutions (6) (Fig. 1). We also created the
Astellas’ oncology drug discovery strategy

Figure 1. Astellas beamline at the High Energy Accelerator Research Organization (KEK). Left: Aerial view of the KEK campus located 9 km north of the Astellas Tsukuba Research Center. Top right: The plan of the PF-AR experimental hall. Astellas beamline (red color) is placed in the NE3 section. Bottom right: The NE-3A deck for X-ray diffraction experiments colored in Red and Gray (Astellas Corporate Brand Color). AR-NE3A, an X-ray beamline with a beam energy of 6.5 GeV ring, is designed for high-throughput macromolecular crystallography which is applied in a structure-based drug design (SBDD). KEK and Astellas jointly developed a fully automated data collection and processing system inside the NE-3A deck. This system can collect X-ray diffraction data sets from more than 200 samples per day by optimizing the schedules of sample exchange, centering, data collection and data processing.

Figure 2. Astellas’ Bioimaging Research Laboratories (BIRL). Upper left: Building of BIRL at Astellas Tsukuba Research Center. Upper right: Automated system for PET tracers developed in-house. Lower left: Positron emission tomography (PET)/computed tomography scanner for small animal studies (Inveon, Siemens). Lower right: PET scanner for large animal studies (SHR-17000, co-developed with Hamamatsu Photonics K.K.).
Bioimaging Research Laboratories at our Tsukuba Research Center in order to enhance our capability in drug discovery and translational sciences (7) (Fig. 2). In addition, we are keen to strengthen our capability in other important technology platforms including proteomics (8) and bioinformatics (9,10).

In view of treatment modality, Astellas had specialized primarily in small molecules, including natural products. Therefore, we in-licensed VelocImmune technology from Regeneron Pharmaceuticals, Inc., in order to efficiently generate fully human monoclonal antibodies (11) and acquired Agensys, Inc., in order to strengthen our drug discovery of antibodies in cancer (12).

**OUR RESEARCH APPROACH**

Based on our in-house research and introduction from other companies in the past few years, our current oncology R&D programs consist of the following three approaches (13):

(i) **Precision medicine**

(ii) **Mechanisms of action with application across multiple tumor types**

(iii) **Leveraging Astellas’ current capabilities in urology and other therapeutic area**

In the past, we took the second and third approaches in our drug discovery. From the second approach, we created YM155, a selective survivin suppressant for multiple tumors (14,15). From the third approach, we created potential treatments for hormone-dependent cancers including YM511, an aromatase inhibitor (16), and YM580, a non-steroidal androgen receptor antagonist (17). Through our experience in these drug discovery programs and subsequent clinical trials, we had fostered the notion that we must deliver novel therapies for improving the health of well-defined populations of patients suffering from a number of cancers.

The establishment of our principles on top of the above-mentioned mindset naturally shifted our research approach in a direction in which we can offer highly effective therapeutic options for precisely defined patient populations based on molecular targeting and precise diagnosis. We call it the precision medicine approach (5,13,18) (Fig. 3).

Precision medicine is becoming a treatment option for certain cancers. In July 2011, the US Food and Drug Administration (FDA) published the draft guidance for in vitro companion diagnostic devices (19). In August 2011, the FDA approved Zelboraf™ (vemurafenib), a kinase inhibitor, for the treatment of patients with unresectable or metastatic melanoma whose tumors express a gene mutation called BRAF V600E together with a diagnostic test to detect such mutation in patients’ melanoma cells (20). The FDA also approved Xalkori® (crizotinib), a kinase inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who express the abnormal anaplastic lymphoma kinase (ALK) gene together with a diagnostic test to detect such abnormal gene (21).

**ACTIVITIES IN OUR RESEARCH SITES**

Astellas has three sites for oncology drug discovery, namely Astellas Pharma Inc. Tsukuba Research Center at Tsukuba, Ibaraki, Japan, OSI Pharmaceuticals, LLC at Farmingdale, NY, USA, and Agensys, Inc. at Santa Monica, CA, USA. The three research sites pursue precision medicine in a diverse manner based on the research platform and research strategy of each site.

Tsukuba Research Center focuses on the creation of small molecules that inhibit the function of molecules which are essential for the survival or growth of tumor cells as a result of either genetic or epigenetic alterations to the drug target molecules themselves or in the presence of certain genetic or epigenetic contexts. In order to create drugs to well-defined patient populations, Tsukuba Research Center is placing significant emphasis on efforts to identify and validate novel molecular targets based on in-house research and external collaborations. It should be noted that these ‘target discovery’ efforts also form the basis of translational research for determination of the right patients. Based on this research style, we created ASP3026, an inhibitor of ALK tyrosine kinase (22,23).

OSI joined Astellas in 2010 (24), and it is pursuing small molecule drug discovery with a different style using different precision medicine strategies. During the development of erlotinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, OSI completed much research to better understand which patients optimally benefit from this therapy and which patients would become refractory or resistant (25–27). This research led OSI to focus on drug discovery and translational research related to epithelial–mesenchymal transition (26,28,29) and compensatory activation mechanisms in oncogenic signal transduction (27,30,31) for both publicly known as well as novel oncology targets. In addition, OSI is doing extensive translational research to identity novel biomarkers for patient selection based on the characterization of gene and protein signatures in responsive tumor cells (32).

Agensys joined Astellas in 2007 (12). Agensys specializes in drug discovery of antibodies for cancer therapy, focusing on the creation of novel monoclonal antibodies from two...
aspects. First, Agensys invested in identifying novel antigen molecules or epitopes which are selectively expressed on the surface of certain sets of tumor cells. These antigen molecules or epitopes are molecular targets for Agensys’ antibodies as well as biomarkers for the selection of the right patients. Agensys is focusing to create antibody–drug conjugates (ADCs, also known as ‘immunoconjugates’) to these antigens. ADC is an antibody covalently attached to a cytotoxic molecule (such as tubulin inhibitor or DNA minor groove binder) via a linker. Once an ADC binds to the antigen on a tumor cell, it is internalized into the tumor cell and the cytotoxic molecule is released to cause cell death (33). This unique combination of novel molecular targets and ADC technology is expected to provide innovative therapeutic options for precision medicine to the patients for whom no effective drug currently exists. Agensys has put three ADCs into clinical trials so far, with AGS-22M6E (also known as ASG-22ME), an ADC targeting nectin-4, as the latest example (34). Secondly, Agensys is using its panel of patient-derived xenografts (PDX) to validate antibody targets in cancers and develop functional antibodies. The panel of over 60 PDX, representing 14 different indications, provides unique preclinical models and allows preclinical evaluation of targets that are required for tumor growth and survival in a particular microenvironment that may not be found or required for growth of xenografts of conventional cell lines. The anti-prostate stem cell antigen antibody AGS-1C4D4 completing a Phase II study in pancreatic cancer is the most advanced example of this approach (35,36).

The chemical compounds and antibodies created by our three research sites, together with in-licensed compounds, form our oncology development pipeline as shown in Table 1.

Table 1. Astellas’ oncology development pipeline

| Code no., generic name | Classification | Therapeutic target | Phase | Origin | Remarks |
|------------------------|----------------|-------------------|-------|--------|---------|
| ASP3550, degarelix     | GnRH receptor antagonist | Prostate cancer | Filed | Ferring Pharmaceuticals |        |
| MDV3100                | Androgen antagonist | Prostate cancer | III   | Medivation |        |
| Erlotinib (Tarceva)    | HER1/EGFR tyrosine kinase inhibitor | Non-small cell lung cancer (first line for patients with EGFR mutation, adjuvant), hepatocellular carcinoma | III | In-house (OSI) | New indication |
| OSI-906                | IGF-1/IR tyrosine kinase inhibitor | Adrenocortical carcinoma (ACC), ovarian cancer, non-small cell lung cancer, hepatocellular carcinoma | III (ACC), II (others) | In-house (OSI) | Ref. (30) |
| ASP4130, tivozanib     | Triple VEGF receptors inhibitor | Renal cell carcinoma (RCC), breast cancer, colorectal cancer | III (RCC), II (others) | AVEO Pharmaceuticals, Inc. |        |
| YM155                  | Survivin suppressant | Breast cancer, non-Hodgkin’s lymphoma | II | In-house (Tsukuba) | Refs (14,15) |
| AC220                  | FLT3 kinase inhibitor | Acute myeloid leukemia | II | Ambit Biosciences Corporation |        |
| AGS-1C4D4              | Antibody (prostate stem cell antigen) | Pancreatic cancer | II | In-house (Agensys) | Refs (34,35) |
| OSI-027                | mTOR kinase inhibitor | Renal cell carcinoma | II | In-house (OSI) |        |
| AGS-16M8F              | Antibody-drug conjugate (ADC) | Cancer | I | In-house (Agensys) |        |
| AGS-5ME                | ADC | Cancer | I | In-house (Agensys) | Co-development with Seattle Genetics |
| ASP1707                | Small molecule | Prostate cancer, endometriosis | I | In-house (Tsukuba) |        |
| ASP3026                | ALK kinase inhibitor | Cancer | I | In-house (Tsukuba) | Refs (21,22) |
| ASP9521                | Small molecule | Prostate cancer | I | In-house (Tsukuba) |        |
| AGS-22M6E              | ADC | Cancer | I | In-house (Agensys) | Ref. (33), Co-development with Seattle Genetics |

GnRH, gonadotropin-releasing hormone; HER1, human epidermal growth factor receptor 1; EGFR, epidermal growth factor receptor; IGF-1R, insulin-like growth factor receptor 1; IR, insulin receptor; VEGF, vascular endothelial growth factor; FLT3, fetal liver tyrosine kinase 3. This table is based on the status of November 2011. Astellas is not developing YM511 or YM580. Astellas has out-licensed FK228 to Gloucester Pharmaceuticals Inc. (currently Celgene Corporation) and YM753 to Oncolys BioPharma Inc.
The three research sites have multiple collaborations that span sites on the basis of research programs as well as platform technologies. The research activities at the sites are coordinated through a team consisting of research leaders, clinical leaders, including medical oncologists, and strategy leaders. This team reviews the research activities of each site and offers ideas for improvement of research programs at each site and to facilitate further collaboration.

In concluding this chapter, we would like to describe how we tackle rapidly progressing fields, taking epigenetics as an example. When molecules involved in epigenetic modification of histone emerged as therapeutic targets, both of our parent companies utilized their natural product technology platform to the discover histone deacetylase inhibitors, namely FK228 and YM753 (37). Since then, a number of epigenetic modification mechanisms have been identified as potential therapeutic targets and biomarkers (38), and we now see this progress as an opportunity for novel drug discovery based on our current mindset and technology platforms.

**FUTURE PERSPECTIVES**

We have described our research activities with emphasis on what we are doing in our research sites. However, our research activities are already based on a number of external collaborations (39), and we seek further opportunity of such collaborations in order to create and deliver novel treatments to cancer patients. We understand that such opportunity is not only in the accomplishments of basic science, but also in the findings and insights derived from clinical practice. While we understand that the feedback of clinical findings to drug discovery in a timely and appropriate manner is a big challenge, it is our hope that we can take this challenge with the readers of this paper.

**Acknowledgement**

Figure 1 was kindly provided by the High Energy Accelerator Research Organization (KEK). We thank many colleagues in Astellas for their support in preparing the manuscript. This paper is dedicated to the late Dr Teruhisa Noguchi, the pioneer of biotechnology and genomics-based drug discovery in Japan who led drug discovery at the former Yamanouchi Pharmaceutical Inc., one of the parent companies of Astellas, as an Executive Vice President.

**Conflict of interest statement**

Yutaka Yanagita, PhD, is an employee of Astellas Pharma Inc. Toichi Takenaka, DVM, PhD, is a Senior Scientific Advisor and a former Chairman of the Board of Astellas Pharma Inc.

**References**

1. Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Yamanouchi and Fujisawa finalize merger agreement. The new company to be named ‘Astellas Pharma Inc.’. *News release*, 24 May 2004.

2. Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Business philosophy, brand mark, and corporate message of Astellas. *News release*, 15 September 2004.

3. Nogimori M. Astellas Pharma Inc. press conference, 3 December 2008.

4. Astellas Pharma Inc. Announcement of VISION 2015. *News release*, 6 December 2006.

5. Tsukamoto S. Astellas Day—Research Part. Astellas Pharma Inc. information meeting-focused on drug discovery research. 29 September 2009.

6. Yamada Y, Hiraki M, Sasajima K, Matsuigaki N, Igarashi N, Amano Y, et al. AR-NE3A, a new macromolecular crystallography beamline for pharmaceutical applications at the photon factory. *AIP Conf Proc* 2010;1234:415–8.

7. Miyoshi S, Mitsuoka K, Nishimura S, Veltkamp SA. Radioisotopes in drug research and development: focus on positron emission tomography. In: Singh N, editor. *Radioisotopes—Applications in Bio-Medical Science*. Rijeka: InTech—Open Access Publisher, 2011:93–114.

8. Yuri M, Hiramoto M, Naito M, Matsumoto M, Morita S, et al. Identification and relative quantitation of an orphan G-Protein coupled receptor SREB2 (GPR85) protein in tissue using a linear ion trap mass spectrometer. *J Proteome Res* 2011;10:2658–63.

9. Kuroda D, Shirai H, Kobori M, Nakamura H. Structural classification of CDR-H3 revisited: a lesson in antibody modeling. *Proteins* 2008;73:608–20.

10. Kuroda D, Shirai H, Kobori M, Nakamura H. Systematic classification of CDR-L3 in antibodies: implications of the light chain subtypes and the VL—VH interface. *Proteins* 2009;75:139–46.

11. Astellas Pharma Inc. and Regeneron Pharmaceuticals, Inc. Astellas licenses Regeneron’s VelocImmune® technology for discovering human monoclonal antibodies. *News release*, 30 March 2007.

12. Astellas Pharma Inc. Astellas to acquire Agensys, Inc. *News release*, 27 November 2007.

13. Nogimori M. Astellas’ growth strategy. Astellas Pharma Inc. press conference, 29 November 2010.

14. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsumo K, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. *Cancer Res* 2007;67:8014–21.

15. Yamanaka K, Nakahara T, Yamanouchi T, Kita A, Takeuchi M, Kiyonaga F, et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. *Clin Cancer Res* 2011;17:5423–31.

16. Kudoh M, Susaki Y, Iyeda Y, Nanya T, Mori M, Shikama H, et al. Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. *J Steroid Biochem Mol Biol* 1996;58:189–94.

17. Kinoyama I, Taniguchi N, Toshimasa A, Nozawa E, Kamikubo T, Inamura M, et al. (+)-(2R,5S,4S)-4-[4-Cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[2-(trifluoromethyl)pyridin-3-yl]perazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist. *J Med Chem* 2006;49:716–26.

18. Christensen CM, Grossman JH, Hwang J. The Innovator’s Prescription: A Disruptive Solution for Health Care. New York: McGraw-Hill, 2009.

19. U.S. Food and Drug Administration. *In vitro companion diagnostic devices, Draft guidance for industry and Food and Drug Administration staff*, 14 July 2011.

20. U.S. Food and Drug Administration. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. *FDA news release*, 17 August 2011.

21. U.S. Food and Drug Administration. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. *FDA news release*, 26 August 2011.

22. Kuromitsu S, Mori M, Shimada I, Kondoh Y, Shindoh N, Soga T, et al. Anti-tumor activity of ASP3026—a novel and selective ALK inhibitor. *Proceedings of the American Association for Cancer Research* 102nd Annual Meeting 2011;676 (Abstract #2821).
23. Kuromitsu S, Mori M, Shimada I, Kondoh Y, Shindoh N, Soga T, et al. Tumor regression induced by ASP3026, a novel small molecule ALK inhibitor, in experimental human lung tumor models. Proceedings of the 70th Annual Meeting of the Japanese Cancer Association 2011;180 (Abstract #P-1324).

24. Astellas Pharma Inc. Astellas Pharma Inc. to acquire OSI Pharmaceuticals, Inc. News release, 16 May 2010.

25. Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, Settinari T, et al. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. *Mol Cell Proteomics* 2005;4:356–76.

26. Thomson S, Buck E, Petti F, Griffin G, Brown E, Rammarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. *Cancer Res* 2005;65:9455–62.

27. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Yale HD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. *Clin Exp Metastasis* 2008;25:843–54.

28. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial–mesenchymal transitions in development and disease. *Cell* 2009;139:871–90.

29. Thomson S, Petti F, Sujka-Kwok I, Mercado P, James Bean J, Monaghan M, et al. A systems view of epithelial–mesenchymal transition signaling states. *Clin Exp Metastasis* 2011;28:137–55.

30. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. *Cancer Res* 2008;68:8322–32.

31. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R); rationale for cotargeting IGF-1R and IR in cancer. *Mot Cancer Ther* 2010;9:2652–64.

32. OSI Pharmaceuticals, Inc. and AVEO Pharmaceuticals, Inc. OSI Pharmaceuticals, Inc. exercises options under discovery and translational research collaboration with AVEO. *News release*, 1 December 2010.

33. Pasqueto MV, Vecchia L, Covini D, Digilio R, Scotti C. Targeted drug delivery using immunoconjugates: principles and applications. *J Immunother* 2011;34:611–28.

34. Satpayev D, Torgov M, Yang P, Morrison K, Shostak Y, Raitano A, et al. Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting nectin-4 for the treatment of solid tumors. Proceedings of the American Association for Cancer Research 102nd Annual Meeting 2011;679 (Abstract #2832).

35. Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, et al. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. *Cancer Chemother Pharmacol* 2011; doi:10.1007/s00280-011-1759-9.

36. Wolpin BM, O’Reilly EM, Ko YJ, Rocha Lima MS, Spratlin JL, Macarulla T, et al. Improved 6-month survival rate in subjects with prostate stem cell antigen (PSCA) positive tumours in a global, randomized phase 2 trial comparing gemcitabine vs. gemcitabine + Ags-1c4d4 (asp6182) in metastatic pancreatic cancer (mPC). *Eur J Cancer* 2011;47(Suppl 1):S469 (Abstract #6591).

37. Masuoka Y, Shindoh N, Inamura N. Histone deacetylase inhibitors from microorganisms: the Astellas experience. In: Petersen F, Amstutz R, editors. *Progress in Drug Research Vol. 66, Natural Compounds as Drugs*, Vol. II. Basel: Birkhäuser Verlag AG 2008;335–59.

38. Rodrigues-Paredes M, Estelier M. Cancer epigenetics reaches mainstream oncology. *Nat Med* 2011;17:330–9.

39. Kyoto University and Astellas Pharma Inc. Kyoto University and Astellas co-research at the Innovation Center for Immunoregulation Technologies and Drugs of Next Generation. *News release*, 3 July 2007.